Categories: News

Optinose to Present at the Jefferies Virtual Healthcare Conference

YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET.

To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.

A replay of the webcast will be available for 30 days following the conclusion of the event.

About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com 
267.521.0531

Staff

Recent Posts

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7…

13 minutes ago

RiDYMO® Designs Cyclic Peptide for “Undruggable” β-Catenin Target Within Two Months

BEIJING, Jan. 8, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has…

2 hours ago

ITRI Opens CES 2025 With Trend-Leading Showcase and Partnership With Reliance Biotech Corporation

LAS VEGAS, Jan. 8, 2025 /PRNewswire/ -- The Industrial Technology Research Institute (ITRI) initiated its presence…

2 hours ago

NOTICE OF DATA BREACH

LOS ANGELES, Jan. 8, 2025 /PRNewswire/ -- Dear members of the STIIIZY community:  Stiiizy, Inc.…

2 hours ago

Ascent Strategy Group Recognized by Modern Healthcare’s Best in Business, Affirms Health Equity Mission Amid Alarming Disparities

Agency Founder nominated Outstanding Agency Professional, Innovator of the Year First public relations agency built…

2 hours ago

Onco-Innovations Provides Information Regarding Exclusive License for Patented Drug with Potential to Enhance Cancer Treatment Options

VANCOUVER, BC / ACCESSWIRE / January 8, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or…

5 hours ago